Changeflow GovPing Healthcare & Life Sciences Nucleic Acid Regulatory Elements Enhance Gene E...
Routine Rule Added Final

Nucleic Acid Regulatory Elements Enhance Gene Expression

Email

Summary

The USPTO published patent application US20260109978A1, filed October 11, 2023 (Application No. 19117712), covering nucleic acid regulatory elements designed to enhance constitutive gene expression across multiple tissue types including liver, muscle, and the central nervous system. The application names eight inventors and discloses expression cassettes, vectors, and methods particularly suited for gene therapy applications. The patent publication makes the application publicly accessible but does not constitute a granted patent right.

“The application relates to nucleic acid regulatory elements that are able to enhance expression of genes constitutively in a variety of tissues, or in particular tissues including liver, muscle, and the CNS.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 264 changes logged to date.

What changed

USPTO published patent application US20260109978A1 for nucleic acid regulatory elements that enhance gene expression constitutively across various tissue types and specifically in liver, muscle, and the CNS. The application discloses expression cassettes and vectors containing these regulatory elements with applications in gene therapy. The filing date is October 11, 2023, with Application No. 19117712.

Biotechnology and pharmaceutical firms developing gene therapy products should monitor this application for potential freedom-to-operate implications if similar regulatory element technologies are employed in their pipelines. Researchers and companies working with viral vectors or nucleic acid delivery systems may find these disclosed elements relevant to their own development programs.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

NUCLEIC ACID REGULATORY ELEMENTS FOR CONSTITUTIVE GENE EXPRESSION AND METHODS OF USE

Application US20260109978A1 Kind: A1 Apr 23, 2026

Inventors

Alexandria Forbes, Josefa Sullivan, Chenjin Jin, Enrico Mossotto, Matthew During, Ce Feng Liu, Dustin Lee, Jessica Schmerler

Abstract

The application relates to nucleic acid regulatory elements that are able to enhance expression of genes constitutively in a variety of tissues, or in particular tissues including liver, muscle, and the CNS. The application further relates to methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. These nucleic acid regulatory elements are particularly useful for applications using gene therapy.

CPC Classifications

C12N 15/113 A61K 31/7088 A61K 48/0058 C12N 5/0619 C12N 5/0652 C12N 5/067 C12N 15/8645 C12N 2750/14143 C12N 2830/008 C12N 2830/34 C12N 2830/50

Filing Date

2023-10-11

Application No.

19117712

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US20260109978A1
Docket
19117712

Who this affects

Applies to
Pharmaceutical companies Manufacturers
Industry sector
3254.1 Biotechnology
Activity scope
Patent filing Gene therapy research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!